Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Should Income Investors Buy This Blue Chip Stock?
08:30am, Sunday, 23'rd Jul 2023
Novartis' exceptional lineup of medicines produced stellar results in Q2. The company's market-beating dividend looks to be sustainable.
Can Novartis Move to New Highs and Sustain Them?
07:11am, Wednesday, 19'th Jul 2023
After more than a decade of trading within a wide and volatile range, it looks like Novartis NYSE: NVS shares will move to a new high and sustain the move.
Why Novartis Stock Spiked Today
04:11pm, Tuesday, 18'th Jul 2023
Novartis released its 2023 Q2 earnings this morning. The revised forecast reflects the robust demand for key products as well as the potential launch of new therapies in its pipeline.
Novartis CEO: We expect our six key drugs to grow ahead of analyst expectations
01:11pm, Tuesday, 18'th Jul 2023
Novartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss what's driving the company's earnings beats, the company's newest technologies, and the 'war for talent.'
Novartis (NVS) Q2 Earnings & Revenues Top, Guidance Raised
12:05pm, Tuesday, 18'th Jul 2023
Novartis (NVS) beats on earnings and sales in the second quarter and raises its annual guidance on strong momentum.
Novartis stock jumps after drugmaker raises full-year guidance, launches $15 billion buyback
11:49am, Tuesday, 18'th Jul 2023
Novartis raised its guidance and announced the buybacks as the Swiss drugmaker reported second-quarter earnings, which topped Wall Street's expectations.
Compared to Estimates, Novartis (NVS) Q2 Earnings: A Look at Key Metrics
10:34am, Tuesday, 18'th Jul 2023
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street e
5 Things to Know Before Markets Open
07:25am, Tuesday, 18'th Jul 2023
Bank of America kicks off a busy day of bank earnings by beating its second quarter profit forecast and retail sales are expected to increase for June. Here's what investors need to know today.
Novartis Stock Climbs. It's All About a Hike in Outlook and $15 Billion Share Buyback.
04:58am, Tuesday, 18'th Jul 2023
The board also endorsed plans to spin off its generic medicines unit Sandoz early in the fourth quarter, subject to shareholder approval.
Q2 2023 Earnings Season Gathers Pace
12:02pm, Monday, 17'th Jul 2023
Q2 2023 Earnings Season Gathers Pace.
Why Novartis (NVS) Might Surprise This Earnings Season
09:47am, Monday, 17'th Jul 2023
Novartis (NVS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Novartis (NVS) to Report Q2 Earnings: Is a Beat in Store?
12:39pm, Friday, 14'th Jul 2023
When Novartis (NVS) reports second-quarter 2023 results, investor focus is likely to be on updates related to Sandoz's spin-off besides the top- and bottom-line numbers.
Novartis (NVS) Entresto Patent Faces Setback, Stock Down
12:30pm, Monday, 10'th Jul 2023
Novartis (NVS) faces a setback in the patent litigation with respect to the blockbuster heart disease drug Entresto. Shares decline.
Why Novartis Stock Slipped on Friday
06:36pm, Friday, 07'th Jul 2023
The pharmaceutical giant suffered a setback with one of its top-selling drugs. The patent for Entresto was invalidated in a court proceeding.
Novartis (NVS) to Divest Xiidra, SAF312 to Streamline Focus
01:43pm, Monday, 03'rd Jul 2023
Novartis (NVS) signs a deal to divest Xiidra and SAF312 (libvatrep) to Bausch + Lomb for $2.5 billion.
